Method of treating cancer using selective estrogen receptor modulators

Abstract

Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

1 - 12 . (canceled) 
     
     
         13 . A method of treating an estrogen receptor positive breast cancer in a subject, wherein the estrogen receptor positive breast cancer is resistant to an estrogen receptor modulator, the method comprising administering a composition comprising (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino}-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol, or a salt thereof. 
     
     
         14 . The method of  claim 13 , wherein the estrogen receptor positive breast cancer is de novo resistant to the estrogen receptor modulator. 
     
     
         15 . The method of  claim 13 , wherein the resistance to the estrogen receptor modulator is acquired. 
     
     
         16 . The method of  claim 13 , wherein the estrogen receptor modulator is tamoxifen, idoxifene, raloxifene or ICI 182,780. 
     
     
         17 . The method of  claim 13 , wherein an effective amount of the composition is administered. 
     
     
         18 . The method of  claim 17 , wherein the effective amount comprises a high dosage. 
     
     
         19 . The method of  claim 18 , wherein the high dosage is more than about 20 mg/kg. 
     
     
         20 . The method of  claim 17 , wherein the effective amount is from about 200 mg/day to about 500 mg/day. 
     
     
         21 . The method of  claim 20 , wherein the effective amount is about 400 mg/day. 
     
     
         22 . The method of  claim 13 , wherein the composition is administered by oral administration, intravenous administration, intradermal injection, intramuscular injection or subcutaneous injection. 
     
     
         23 . The method of  claim 13 , further comprising administering an effective amount of at least one compound selected from the group consisting of a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6 inhibitor), an antiestrogen, a ligand of retinoic acid or retinoxic X receptor, an antiprogestin, an antiandrogen, vitamin D or metabolite thereof, a farnesyl transferase inhibitor, a PPARα or gamma agonist and a MAP kinase inhibitor.